Patent: 10,111,954
✉ Email this page to a colleague
Summary for Patent: 10,111,954
Title: | Combination therapy for inducing immune response to disease |
Abstract: | The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-.alpha.), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL.TM. complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3.times. anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. |
Inventor(s): | Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Rossi; Edmund A. (Woodland Park, NJ), Rossi; Diane (Woodland Park, NJ), Hansen; Hans J. (Diamondhead, MS) |
Assignee: | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) |
Application Number: | 15/287,329 |
Patent Claims: | see list of patent claims |
Details for Patent 10,111,954
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2032-08-14 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2032-08-14 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2032-08-14 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2032-08-14 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2032-08-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |